Results 231 to 240 of about 881,326 (300)

Exercise Training Transiently Increases Gut Microbiota Diversity and Short-Chain Fatty Acid Production in a Diet-Dependent Manner in Healthy Adults. [PDF]

Microorganisms
Hwang S, Wu X, Yoon JW, Jeon IC, Hwang YI, Kim KS, Park S.   +6 more
europepmc   +1 more source

Impact of Single Viable Hepatocellular Carcinoma ≤ 3 cm on Survival After Liver Transplantation

ANZ Journal of Surgery, EarlyView.
An Australian multi‐centre cohort study shows significantly lower 5‐year HCC‐specific mortality for those with no viable disease compared to those with a single viable tumour ≤ 3 cm, on imaging prior to transplantation. A lower AFP level and complete response on mRECIST criteria also reduced risk.
Lauren C. Y. Tang, Eunice Lee, Avik Majumdar, Ted Stoklosa, Danny Con, William Chung, Emily Nash, Adam Testro, Michael Fink, Simone Strasser, Ken Liu, David G. Bowen, Marie Sinclair   +12 more
wiley   +1 more source

The Role of FGF1 in Chronic Liver Diseases. [PDF]

Biomedicines
Liu T, Yu M, Han L, Wu J, Liu D, Tan Y.
europepmc   +1 more source

Economic Evaluation of Prolonged Hypothermic Oxygenated Machine Perfusion Enabling Daytime Liver Transplantation

Artificial Organs, EarlyView.
DHOPE‐PRO enabled daytime liver transplantation with comparable one‐year transplantation‐related costs versus short‐duration DHOPE. Higher perfusion costs were offset by lower surgery‐related costs, suggesting DHOPE‐PRO can improve scheduling logistics without increasing overall hospital costs.
Linda C. Woltjes, Marijke I. Bonnema, Isabel M. A. Brüggenwirth, Veerle A. Lantinga, Christian S. van der Hilst, Vincent E. de Meijer, on behalf of the DHOPE‐PRO Trial Investigators, Marieke T. de Boer, Carlijn I. Buis, Suomi M. G. Fouraschen, Hermien Hartog, Frederik J. H. Hoogwater, Vincent E. de Meijer, Joost M. Klaase, Ruben H. J. de Kleine, Mark Meerdink, Maarten W. Nijkamp, Hans Blokzijl, Frans J. C. Cuperus, Frans van der Heide, Daphne M. Hotho, Frederike G. I. van Vilsteren, A. Boudewijn de Vries, Ilhama F. Abbasova, Johannes P. van den Berg, Jan‐Willem H. L. Boldingh, Meine H. Fernhout, Manon Klaver, Ernesto R. R. Muskiet, Koen M. E. M. Reyntjens, Jaap J. Vos, Miriam Zeillemaker, Isabel M. A. Brüggenwirth, Veerle A. Lantinga, Bianca Lascaris, Adam M. Thorne, Silke B. Bodewes, Sabrina Stimmeder, Ton Lisman, Wouke N. Kuiper, Vivianne E. Veenma, Minou de Bree, Kirsten F. Ma, Roman Kalashnik, Giel M. Van Vliet, Kees Wieriks, Carin Biel, C. Willemijn Binnekamp   +47 more
wiley   +1 more source

Stero-bile Acids and Bile Alcohols

Stero-bile Acids and Bile Alcohols
openaire   +3 more sources

The gut-liver-immune axis: structural basis, cellular architecture, molecular mediators, and disease-specific manifestations. [PDF]

Front Immunol
Yoon SJ, Eom JA, Suk KT.
europepmc   +1 more source

Carriage of the Laboratory of Genetics and Physiology Protein 2 Q425R Variant Reduces Liver Disease Severity in European Patients With Chronic Hepatitis Delta

Alimentary Pharmacology &Therapeutics, EarlyView.
In patients with chronic hepatitis Delta, the LGP2 Q425R variant (rs2074158 CC/CT genotypes), associated with an enhanced interferon response in vitro, becomes progressively less frequent as liver disease advances from no cirrhosis to cirrhosis, and to cirrhosis with progressive increase of portal hypertension evaluated by thrombocytopenia.
Sara Cmet, Elisabetta Degasperi, Annarosa Cussigh, Elisabetta Fontanini, Maria Paola Anolli, Floriana Facchetti, Riccardo Perbellini, Dana Sambarino, Sara Colonia Uceda Renteria, Annapaola Callegaro, Davide Bitetto, Elisa Fumolo, Ezio Fornasiere, Elena Garlatti Costa, Edmondo Falleti, Pietro Lampertico, Pierluigi Toniutto   +16 more
wiley   +1 more source

Physiological Functions of Freshwater Clam Extracts and the Exploration of Their Bioactive Compounds. [PDF]

Foods
Kuwano K, Hata M, Umeki M, Mochizuki S, Oda H, Shimazoe T.   +5 more
europepmc   +1 more source

ALBI‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab

Alimentary Pharmacology &Therapeutics, EarlyView.
ALBI‐6, a novel score combining albumin–bilirubin grade and interleukin‐6, showed improved prognostic discrimination compared with established scores in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab, supporting its potential use for risk stratification in this setting.
Paula Bark, Lucas Wiesmann, Simon Johannes Gairing, Kateryna Shmanko, Lukas Müller, Maximilian Moos, Fabian Stöhr, Dirk Graafen, Tilman Emrich, Felix Hahn, Daniel Pinto dos Santos, Bernhard Scheiner, Victoria Berit Berger, Matthias Pinter, Valentina Zarka, Florian P. Reiter, Andreas Geier, Najib Ben Khaled, Alexander Philipp, Christoph Springfeld, Aurelie Tomczak, Michael T. Dill, Constantin Scholz, Jens Mittler, Hauke Lang, Beate Katharina Straub, Roman Kloeckner, Tobias Bäuerle, Christian Markus Lange, Arndt Weinmann, Peter Robert Galle, Friedrich Foerster   +31 more
wiley   +1 more source

Bidirectional interplay between gut and liver in inflammatory bowel disease and hepatobiliary conditions. [PDF]

Clin Exp Med
Abdulla A, Sheikhnoor AM, Ferrao K, Stiles LI, Mehta KJ.   +4 more
europepmc   +1 more source